This mechanism may explain the positive response to tamoxifen observed in this study, in which a patient with an ERβ-positive prolactinoma exhibited the greatest reduction in prolactin level and tumor shrinkage in response to tamoxifen treatment. This evidence concerns the gene PRL and neoplasm.